I seen that and looks like this is going to turn out to be the revenge on Roche or something like that
maybe Roche will get pi$$ed off enough just to open their vaults the widest they ever have and pay the golden price tag for PS Targeting
Now I must return to my day job, though digging deeper into who is behind "dozens of collaborators" is just as exciting and who would have thought it would take this long after Sept 2012? not me but we must be patient I guess
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!